Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
Photo: Michael Sohn/POOL/AFP via Getty Images
Developers for COVID-19 therapeutics, vaccines and testing do not need to conduct large and lengthy clinical trials to address new coronavirus variants, new guidance from the Food and Drug Administration said Monday.
Why it matters: Mutated versions of the coronavirus threaten to prolong the pandemic, possibly for years to come — especially if current treatments are rendered less effective. The FDA's updated recommendations could greatly accelerate the emergency authorization process to address these concerns.
The state of play: The vaccines authorized by the FDA — produced by Moderna and Pfizer-BioNTech — have still been found to be effective against the new variants, but both companies have announced plans to modify their vaccines to better protect against mutations.
- Any adjustments developers make for new variants would need small trials, like those required for annual flu vaccines.
- The agency has identified a few coronavirus tests that are known to be impacted by emerging viral mutations, "though at this time the impact does not appear to be significant," according to the guidance.
Between the lines: The new guidance recommends that developers consider the potential impact of viral mutations during phase 2 and phase 3 clinical trials, and it asks these companies to continuously monitor genomic databases.
- The agency has "already been communicating with individual medical product sponsors to provide information and scientific advice as they evaluate the impact of SARS-CoV-2 variants on their products," the guidance says.
What they're saying: "By issuing these guidances, we want the American public to know that we are using every tool in our toolbox to fight this pandemic, including pivoting as the virus adapts," Janet Woodcock, acting commissioner of the FDA, tweeted on Monday.
- "We need to arm health care providers with the best available diagnostics, therapeutics and vaccines to fight this virus. We remain committed to getting these life-saving products to the frontlines."